back to company universe
AI agents

Persist AI

It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.

sources
1
Evidence entries preserved.
affiliations
1
Y Combinator
competitors
6
Mapped from High Signal graph features.
status
generated
D1 lookup
last updated
2026-07-15
16:41 UTC
source evidence
Why this company exists here

Y Combinator

yc-company-directory #5194

It takes 5 years for pharma to develop long lasting drug injections for chronic diseases like cancer and diabetes. Persist uses AI-driven automation to reduce formulation development time down to 2 years, a ~50% reduction.

source
generated read
High Signal interpretation

Persist AI is classified as AI agents from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.

offline extraction
Product facets
pharmaAI-driven automationlong lasting drug injectionsPersist AIchronic diseases
mapping method
Similarity graph

Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.

discovery cluster

Companies similar to Persist AI

AI agents · 6 peers

A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.

Altay Therapeutics

match 65

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affe

shared product terms: develop, drug, chronic, disease; shared affiliation: Y Combinator

RinkD&S

match 52

B2B Data - Driven Development and manufacturing automation platform

shared extracted concept terms: driven, automation; shared product terms: driven, automation, development; shared product theme: workflow automation; same category: AI agents

Redivivum

match 52

Redivivum is developing the leading AI-driven automation solution to tackle the labor and expertise shortages in resale operations for the fashion industry.

shared extracted concept terms: driven, automation; shared product terms: develop, driven, automation; shared product theme: workflow automation; same category: AI agents

CIPRA.ai

match 52

CIPRA.ai provides AI-driven precision chronic care and scalable patient engagement to improve outcomes in hypertension, diabetes, and other cardiometabolic diseases.

shared extracted concept terms: driven, chronic; shared product terms: driven, chronic, diabete, disease

Ochre Bio

match 45

Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.

shared extracted concept terms: chronic, disease; shared product terms: develop, chronic, disease; shared affiliation: Y Combinator

Mayan

match 45

We help Amazon sellers grow their business with our data-driven automations. We are starting out with advertising and inventory. From there, we're moving to other avenues that help accelerate brand growth!

shared extracted concept terms: driven, automation; shared product terms: driven, automation; shared product theme: workflow automation; same category: AI agents; shared affiliation: Y Combinator